GeNeuro SA Company Profile

11:59 EST 18th December 2018 | BioPortfolio

News Articles [10 Associated News Articles listed on BioPortfolio]

GeNeuro Confirms Potential of Novel pHERV-K Antibodies for ALS in Collaboration with NINDS, Secures Rights

Following successful CRADA collaboration data in preclinical ALS models, GeNeuro exercises option with the National Institute of Neurological Disorders and Stroke (NINDS) to secure worldwide devel...

GeNeuro Reports 2018 Half-Year Results and Provides Corporate Update

Robust cash position of €17.3 million as of June 30, 2018 All clinical and research activities funded through 3Q2019 Regulatory News: GeNeuro (Paris: GNRO) (Euronext Paris: CH0308403085 GNRO), a b.....

GeNeuro to Present New Data Supporting Role of Human Endogenous Retroviruses in Type 1 Diabetes at American Diabetes Association's (ADA) 78th Scientific Sessions

Regulatory News: GeNeuro (Paris:GNRO) (Euronext Paris: CH0308403085 GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, including multiple sclero...

Servier declines rights to GeNeuro's GNbAC1

GeNeuro: Financial Information and Business Update for the Second Quarter 2018

Q2 2018 operating revenues of €4.34 million (+195% vs. Q2 2017) €17.11 million cash at June 30, 2018 6-month results for Type 1 Diabetes clinical trial expected end September 2018 Regulatory News:...

GeNeuro Presents Phase 2b Data Demonstrating Neuroprotective Effect of GNbAC1 in Multiple Sclerosis Patients at ECTRIMS 2018

Positive effects observed on key neuroprotection endpoints related to MS disease progression Neuroprotective effects also seen in non-active MS patients Confirmation of safety and tolerability Reg...

Moving the Needle Forward on Multiple Sclerosis Research (Webinar)

Are we closer to finding a cure for MS? Attend this webinar to find out. July 11, 2018 | 10:00am ET Discover insights from the experts at GeNeuro, a clinical stage pharmaceutical company developi...

GeNeuro SA GNRO Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 13082018] Prices from USD $250

SummaryGeNeuro SA GeNeuro is a clinical stage pharmaceutical company that manufactures therapeutic product pipeline for disorders of the nervous system. The company provides treatments against inflamm...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [2 Associated Companies listed on BioPortfolio]


GeNeuro is a Swiss-based company created by Eclosion in 2006 as a spin-off of bioMérieux and co-funded by Eclosion and the Institut Mérieux. GeNeuro is developing first-in-c...

GeNeuro SA

More Information about "GeNeuro SA" on BioPortfolio

We have published hundreds of GeNeuro SA news stories on BioPortfolio along with dozens of GeNeuro SA Clinical Trials and PubMed Articles about GeNeuro SA for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of GeNeuro SA Companies in our database. You can also find out about relevant GeNeuro SA Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record